Novo Nordisk Rejects Claim It Influences GLP-1 Market

By Aneeta Mathur-Ashton · April 29, 2026, 5:35 PM EDT

Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an...

To view the full article, register now.

Documents

Case Information

Case Title

Strive Specialties, Inc. v. Eli Lilly & Company et al

Case Number

5:26-cv-00155

Court

Texas Western

Nature of Suit

Anti-Trust

Date Filed

January 14, 2026

Recent Articles By Aneeta